Coffee Reduced Risk of Melanoma, Particular in People with Altered GSTM1 and GSTT1 Gene

Intake of coffee regularly may have a positive effect in reduced risk of Melanoma, particular in healthy people with alternated genes GSTM1 and GSTT1 expression, a renowned institute study suggested.

Melanoma is a type of malignant skin cancer caused by DNA damage, most often caused by ultraviolet radiation from sunshine or tanning beds inducing irregular growth of skin cells.

Coffee, becoming a popular and social beverage all over the world, particularly in the West, is a drink made from roast bean from the Coffea plant, native to tropical Africa and Madagascar.

According to the Istituto Dermopatico dell' Immacolata, in compared to low coffee intake, high frequency of coffee drinking (>once daily) with ≤7 times weekly, showed a significantly lower risk of melanoma.

Interestingly, in the group people with GSTM1 and GSTT1 null polymorphisms(altered gene expression) subjects, coffees showed an extreme high protective effect against forming of Melanoma.


Also in the searching of PubMed and EMBASE databases from the earliest available online indexing year to March 2017 for a dose-response meta-analysis on prospective cohort studies, researchers at the Jagiellonian University Medical College insisted that linear dose-dependent are associated to the development of melanoma risk and total coffee consumption.

Risk of melanoma is reduced by 3% for every cup of coffee intake per day.

Dr. Micek A, the lead author in the joint study said, "(According to) a total of seven studies eligible for meta-analysis were identified that comprised 1,418,779 participants and 9211 melanoma cases,......coffee intake may be inversely associated with the incidence of melanoma".

Further in the demonstration of 2 case-control studies (846 MM patients and 843 controls) and five cohort studies (including 844,246 participants and 5,737 MM cases), in compared the lower and higher caffeine intake daily, caffeinated coffee showed a pooled relative risk (RR) of 0.81.

Risk of an additional cup of coffee caffeine consumption, the relative odds ratio of the risk of melanoma deceased by 0.955
Importantly, the study found no correlated and linear dose-dependent of decaffeinating coffee and risk melanoma regardless of the volume of daily intake in teasing subjects.

Taking all together, there is no doubt that caffeine coffee has a significant effect in reduced risk of melanoma in healthy and altered GSTM1 and GSTT1 expression subjects in linearly dose-dependent
manner.


Natural Medicine for Fatty Liver And Obesity Reversal - The Revolutionary Findings To Achieve Optimal Health And Lose Weight

How To Get Rid Of Eye Floaters
Contrary To Professionals Prediction, Floaters Can Be Cured Naturally

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months

Back to Kyle J. Norton Homepage http://kylejnorton.blogspot.ca


Author Biography
Kyle J. Norton (Scholar, Master of Nutrition, All right reserved)
Health article writer and researcher; Over 10.000 articles and research papers have been written and published online, including worldwide health, ezine articles, article base, health blogs, self-growth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bioscience, ISSN 0975-6299.

Sources
(1) The protective effect of coffee consumption on cutaneous melanoma risk and the role of GSTM1 and GSTT1 polymorphisms by Fortes C1, Mastroeni S, Boffetta P, Antonelli G, Pilla MA, Bottà G, Anzidei P, Venanzetti F.(PubMed)
(2) Caffeinated and decaffeinated coffee consumption and melanoma risk: a dose-response meta-analysis of prospective cohort studies by Micek A1, Godos J2, Lafranconi A3, Marranzano M2, Pajak A1(PubMed)